Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7204239 + Tirzepatide in Obesity or Overweight
NCT06965413Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- May 2025
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of emugrobart in obesity and Overweight (4 arms), sponsored by Roche. Primary endpoint: Percent Change From Baseline in Body Weight at 48 weeks. Started May 2025; status: active, not recruiting.
02
Drugs
emugrobart
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06965413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06965413.